Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthriti

Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthriti

Item

http://www.wikidata.org/entity/Q34476423

Q34476423

about

Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis Pharmacological basis for the therapy of pain and inflammation with nonsteroidal anti-inflammatory drugs NSAIDs: gastroprotection or selective COX-2 inhibitor?Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers Cyclooxygenase inhibition: between the devil and the deep blue sea The cyclooxygenase-2 inhibitors: safety and effectiveness.Low back pain (acute).Aspirin and other anti-inflammatory drugs.Non-steroidal anti-inflammatory drug toxicity in the upper gastrointestinal tract.Bioavailability and pharmacokinetics of oral meloxicam in llamas COX-2 inhibitors compared and contrasted.Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety.Cost-effectiveness of strategies for primary prevention of nonsteroidal anti-inflammatory drug-induced peptic ulcer disease.Review article: NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors.Meloxicam and selective COX-2 inhibitors in the management of pain in the palliative care population.Network Meta-Analysis Comparing Relatively Selective COX-2 Inhibitors Versus Coxibs for the Prevention of NSAID-Induced Gastrointestinal Injury.Meloxicam in rheumatoid arthritis.Transition of treatment for patients with extra-abdominal desmoid tumors: nagoya university modality.NSAID-Induced Enteropathy in Rheumatoid Arthritis Patients with Chronic Occult Gastrointestinal Bleeding: A Prospective Capsule Endoscopy Study.Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors.Is the large simple trial design used for comparative, post-approval safety research? A review of a clinical trials registry and the published literature.Effects of Tribulus terrestris on monosodium iodoacetate‑induced osteoarthritis pain in rats.Steady-state pharmacokinetics of lithium in healthy volunteers receiving concomitant meloxicam.Celecoxib and ankylosing spondylitis.COX-1 and COX-2 products in the gut: therapeutic impact of COX-2 inhibitors.Effects of meloxicam on platelet function in healthy adults: a randomized, double-blind, placebo-controlled trial.Indomethacin versus meloxicam for prevention of heterotopic ossification after total hip arthroplasty.Assessment of the safety of selective cyclo-oxygenase-2 inhibitors: where are we in 2003?Pharmacokinetics of meloxicam in patients with juvenile rheumatoid arthritis.Meloxicam and risk of myocardial infarction: a population-based nested case-control study.Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2.The Risk of Gastrointestinal Bleed, Myocardial Infarction, and Newly Diagnosed Hypertension in Users of Meloxicam, Diclofenac, Naproxen, and Piroxicam

P2860

Q24646764-280352E1-FF43-4A3A-B36F-94CBDE81D2E0 Q24792554-98DB5C5E-23A6-430F-8B31-BAEB6F8DBD85 Q28168965-B2E5599B-7333-4EC6-9FAA-054E03972AE0 Q28168971-12265965-B70A-40AB-9706-1E49BA586A9E Q28192790-7BAA97D3-6034-4552-81DB-3B1FF428BBDB Q33735395-F1EF3B77-5DA0-4EB1-8045-46B9190D5BB0 Q33891708-E7993AD5-BF4C-4CB6-B485-F84EBD4F12AB Q34036177-61AAE810-D9D6-4203-BA0D-1B6D0789EFFF Q34095700-D085B81E-2FAF-4621-B3C2-D12655527093 Q34312685-57CC0CF0-6E1E-4382-BEC8-FE677C4704F6 Q34515513-0C5FDE4E-C84D-43AF-A809-31BC2A5CB482 Q34561392-A7E2862E-6F3F-4A25-9944-FDFFA5187073 Q34745694-153B3302-C880-449C-A241-89A0444B8768 Q35058190-516B081E-EB40-4931-844C-C7C5239269FF Q35196870-52D6114A-952F-4C2A-992C-641DB60FF2B3 Q36195392-9396F56D-5BE4-4CC3-AB2F-176C4DE23259 Q36544898-38AD1743-F8C8-49FB-9816-C4EA852158FB Q37016976-55BBA2A7-3E0A-4371-BD46-D2EA2A4F8A2F Q37409122-E4A698E2-B2F5-464D-85B3-34553238475C Q37893966-A4CF0814-7FD7-42FA-BFBB-966058351124 Q37924275-23654EB5-8146-4F59-B7A9-C6E5A7B69E24 Q40076500-B4377DDD-C767-466F-B492-1F119F39D1BB Q41611791-C22A2484-B427-4A4F-A373-8F50E3EDCD24 Q43061712-7AF8AABD-7A60-4A44-B583-34068B9265CE Q43086302-6A98E677-5D03-4691-BA61-0BCCB9525F13 Q44089725-5F1DC9B9-3FCF-44E4-9E95-0A3591B95B6B Q44381963-F0F88019-70F1-488C-8E13-22F90565B644 Q44808671-DE6FA1F2-EB39-4D6C-8BC2-B06959088976 Q45001564-F17265E1-F577-4AF0-BC42-BCBDF2E8A14B Q50067297-88126341-5F06-4023-A93F-D98F1256B951 Q53342780-A5FE2F19-D8E7-4637-AB3F-783008DA3160 Q57950903-92E356CF-4F87-4CAB-BA50-4E31B2C75E30

P2860

Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthriti

Item

http://www.wikidata.org/entity/Q34476423

description

1998 nî lūn-bûn

@nan

1998 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

1998 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

1998年の論文

@ja

1998年論文

@yue

1998年論文

@zh-hant

1998年論文

@zh-hk

1998年論文

@zh-mo

1998年論文

@zh-tw

1998年论文

@wuu